

# NUCLEAR MEDICINE

gradual, 2x45'

Istvan Szilvási

Dept. of Nuclear Medicine  
Semmelweis University

2013

# DEFINITION OF NUCLEAR MEDICINE

Medical applications of unsealed radioisotopes for

Diagnostic

Therapeutic

Research

into the living organism!

(Not the brachytherapy. In vitro diagnostic use??)

Independent medical specialty (5 yr specialization)

Diagnosis + Therapy of diseases (not only imaging)

# HEVESY GYÖRGY

## Georg von Hevesy

Isotopes:

same chemical (and biochemical)  
characteristics, no biological differences

First use in biological systems (1924)

Tracer principle: to follow functions  
small amount, same biochem.  
radioactive labelled

„Father of nuclear medicine”

Nobel prize in chemistry 1943



# RADIOISOTOPES IN MEDICINE

Isotope: same number of protons

chemically the same element! (e.g. C-11, O-15)

Proton : neutron. Stability? !

Unstable nucleus changes: radiation

Types of isotopes (and radiations)

plus protons:

positron emission

meets electron: annihilation  $2 \times 511 \text{ keV}$

K-electron capture

characteristic Xray + gamma

plus neutrons:

beta (from nucleus) + gamma

Production: cyclotron and reactor (arteficial isotopes)

# IMPORTANT RADIONUCLIDES

**Diagnostic:** electromagnetic radiation (photons)

plus neutron:

Tc-99m, I-131, Xe-133: gamma

plus proton:

- Ga-67, In-111, I-123, Tl-201: Xray +gamma

- C-11, N-13, O-15, F-18, Ga-68: annihilation

**Therapeutic:** particle (absorption in tissue: dose)

beta: Y-90, I-131, Sm-153, Re-186,-188...

(alpha: At-211, Bi-212, Ra-223)

# ADVANTAGES OF Tc-99m

(m=metastable)  
in 80 % of SPECT examinations

## Physical (for detection)

140 keV ideal for gamma camera (70-400 keV)  
monoenergetic (ideal for imaging)

## Biologic: low radiation dose

high amount of activity, No. of photons (Poisson)  
"pure" gamma (from Mo-99), T1/2: 6 h, optimal

## Practical

from generator (Mo-99) elution, phys. saline (!)  
stable complexes with many molecules

# RADIOPHARMACEUTICALS

Organ- tissue- molecular-  
**function-specific labelled molecules**

## **Diagnosis:**

Functions: organ, tissue, molecular (quantitative)  
Tissue characterization – identification

## **Therapy:**

targeted, selective radiation therapy  
(high dose: continuous radiation)  
„tailored”, „personalized”

## **Role of radioisotope**

for detection or for therapy

**„Theranostics”**: the same molecules (I-131, SMS,..)

# DETECTION: IMAGING

## **Gamma camera**

- scintillation crystal, rectangular detector
- static and dynamic acquisitions
- spot, whole-body
- planar or SPECT (emission CT: projections)
- ECG-gated
- dedicated for organs

## **Positron camera: PET („double-photon ECT“)**

- ring detectors (small crystals)
- 16-21 cm axial FOV
- coincidence detection (3D data acquisition)



# DETECTION: NON-IMAGING

**Ex vivo measurements** of biological samples  
e.g. clearance (blood), Schilling test (urine)

## **Small dedicated instruments**

Dynamic function studies (e.g. kidney, heart)

Thyroid uptake test

radioiodide therapy, activity calculation

Intraoperative probes for localization

e.g. sentinel lymph node detection

# SCINTIGRAPHY

In vivo imaging of distribution of activity  
(radiopharmaceuticals = functions)

planar or SPECT

static or dynamic

gated or ungated

whole body

pinhole

dedicated (heart, breast)

# PET vs. SPECT

## double-photon single-photon

1. More sensitive (no collimator!)
2. Spatial resolution is better (anatomic details)

SPECT: 10 mm, PET: 3 - 4 mm

3. Quantitative

absolute (e.g. mL/min/g, mol/min/g)

4. **Biomolecules !!!**

C-11, N-13, O-15, F-18, (but Ga-68)

(glucose, tyrosine, thymidine, H<sub>2</sub>O, etc.....)

**SLICE OF LIFE**

# DISADVANTAGES OF NM

- Geometric-spatial resolution (anatomy?)  
contrast (see stars !)  
e.g. thyroid but liver
- Radiation burden  
Indication !!! (other, non-ionizing ?)  
ALARA principle  
Diagnostic reference levels  
(gravidity, children)  
risk-benefit

# HYBRIDE IMAGING SYSTEMS

Function + morphology

on the same gantry: „simultaneous” (image fusion?)

Improvement of diagnostic capabilities

**1 + 1 = 3 !**

PET/CT (only)

SPECT/CT („good” SPECT= SPECT/CT)

role of CT: localization + attenuation correction

„low dose” ! (non diagnostic CT)

PET/MR

no radiation (paediatrics, brain, oncology, ...?)

# PET/MR

- No ionizing radiation
- Pediatric, breast, serial
- Soft-tissue contrast
- Functional MR techniques
  
- Expensive
- Indications ?

# FUNCTIONS

**Organ:** heart, liver, ventilation, blood flow, lymph flow

e.g. kidney: glomerular, tubular, secretion,  
urinary flow, clearance

**Cellular:** tissue characterization

e.g. antigens, receptors, enzyme expressions

**Molecular:** biochemical, metabolic processes

e.g. angiogenesis, apoptosis, hypoxia, etc.

**Genetic:** DNS („nuclear imaging”), RNS  
oligonucleotides

# ROLE OF NM IMAGING

## **Functional imaging**

organ- cell- biochemical functions  
tissue characterization  
molecular imaging (at molecular level)

## **Radiology: morphological**

co-operation  
PET/CT, SPECT/CT  
education  
diagnostic algorithms

Noninvasive methods (i.v. injections + radiation)

no toxic effect (low amount: pico-, nanomolar)



# IMPORTANCE OF MOLECULAR IMAGING

Disease: functional changes

Function before morphology

Early diagnosis

Targeted diagnosis

Targeted therapy

# MOLECULAR IMAGING METHODS

- Nuclear medicine !
  - MR
  - Optical
  - CT
  - UH

# MOLECULAR IMAGING

Functions at molecular et cell levels

„commodore” in molecular imagin: PET



Reasons:

pico-nano-femto-molar amount

hundreds of biomolecules can be labelled

cliniclly today: 30-40 substances

# MOLECULAR NUCLEAR MEDICINE TARGETS

Enzymes – substrates

FDG, FLT, FET, FEC, FDOPA

Receptors – ligands

D2, SMS

Antigens – antibodies (fragments)

PSA, CEA, TAG72, CD20

Transport proteins – substrates

NIS

Deposits – binding molecules

beta-amyloid

# PERSPECTIVES

- Apoptosis
- Angiogenesis
- Hypoxia
- MDR
- ....
- Oncogens
- Genexpressions

Etc.

Annexin V, ML

VEGF, integrin antibodies

misonidazol, FMISO

sestamibi

F-18 oligonukleotides

Gen therapy (reporter gen)

HSV-Tk co-expression with

F-18-deoxythymidine

# IMMUNOSCINTIGRAPHY

- Monoclonal antibodies
- Fragments: Fab, humanized, chimeric, affibody, minibody (specific group)
- Chelating agents: Tc-99m, In-111 or I-131
- Clinical use:  
colorectal, prostate, ovarian cancers
- (NHL-Radioimmunotherapy  
antibodies against CD20+ B-lymphocytes)

# RADIONUCLIDE THERAPY

- Specific
- Effective
- Low side-effects
- Excellent palliation
- Repeatable
- Relatively inexpensive
- Individual dosis